New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma

**New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma**

Multiple Myeloma

#BCMA #CD27#CARTCellTherapy #RRMM #MM #MultipleMyeloma #CART

Relapsed and refractory multiple myeloma (RRMM) is a challenging blood cancer that poses significant obstacles for patients. Although several BCMA (B-cell maturation antigen) targeting CAR-T cell therapies have been developed, achieving long-term remission and extended survival remains difficult. The recent introduction of CD27-armored BCMA CAR-T—CBG-002—by a Chinese medical team brings new hope for RRMM patients. Based on preclinical data, this therapy shows promising anti-myeloma activity, with Phase I clinical trial results further validating its efficacy and safety.

Research Highlights

CBG-002 is an innovative therapy that enhances traditional BCMA CAR-T by adding a CD27 costimulatory domain. The inclusion of CD27 improves CAR-T cell persistence and activity, contributing to stronger anti-cancer effects. Recently published Phase I research in Cancer Immunology Research indicates that this CD27-armored BCMA CAR-T therapy is not only well-tolerated but also shows notable efficacy in RRMM patients.

The study enrolled 11 RRMM patients, all of whom had undergone three or more prior treatments, with a median age of 54. The results showed that 81.8% of patients experienced only mild cytokine release syndrome (CRS) and no severe neurotoxicity. Even at a low dosage level (1-3×10^6 CAR-T cells/kg), CBG-002 achieved a high overall response rate (ORR) of 81.8%, with 45.5% of patients reaching stringent complete remission.

Future Outlook

The Phase I study of CBG-002 not only confirmed its efficacy but also demonstrated advantages in production time and cost. Compared to current products on the market, CBG-002 has a shortened production cycle of just 10 days, making it a timely and affordable treatment option for more patients. Amid global progress in CAR-T cell therapies, the innovation by this Chinese medical team positions it as a significant force in advancing cancer research worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

 #MultipleMyeloma #CancerResearch #Immunotherapy  #ChinaBiotech #Oncology